GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including telehealth services. The company serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is based in Santa Monica, California.
IPO Year: 2020
Exchange: NASDAQ
Website: goodrx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/9/2024 | $10.00 | Outperform → Strong Buy | Raymond James |
5/23/2024 | $8.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
5/16/2024 | $10.00 | Mkt Perform → Outperform | Raymond James |
4/10/2024 | $9.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
3/25/2024 | $7.50 → $10.00 | Equal Weight → Overweight | Wells Fargo |
3/1/2024 | $7.00 → $10.00 | Neutral → Overweight | JP Morgan |
2/26/2024 | $8.00 | Outperform | Leerink Partners |
1/2/2024 | $8.00 → $4.50 | Buy → Underperform | BofA Securities |
8/10/2023 | $9.50 | Neutral → Buy | DA Davidson |
7/31/2023 | $6.50 → $12.00 | Market Perform → Outperform | TD Cowen |
SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G - GoodRx Holdings, Inc. (0001809519) (Subject)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
First over-the-counter daily birth control pill now available to order via GoodRx's new direct-to-consumer shopping experience Today, GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., announced the rollout of its new e-commerce solution, with Opill® as its launch partner. This new seamless direct-to-consumer shopping experience allows consumers to order eligible health products and medications on the GoodRx platform and have them shipped directly to their door. Not only does this mark GoodRx's entry into the over-the-counter (OTC) market, but it offers valuable partnership opportunities for consumer health and pharmaceutical brands looking to leverage GoodRx's ex
First weight loss medication with an exclusive low cash price available on the GoodRx platform GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., announced today that QSYMIA® (phentermine and topiramate extended-release capsules CIV) is available for a low cash price in more than 70,000 retail pharmacy locations nationwide exclusively via GoodRx. This initiative not only propels GoodRx's momentum in weight loss solutions, but also broadens its portfolio in offering significant savings on brand-name medications, making obesity treatment more accessible and affordable for millions. According to the CDC, more than two in five U.S. adults have obesity, and untreated
IQVIA CFO brings 39 years of healthcare and finance expertise to GoodRx GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced the election of Ronald E. Bruehlman to its Board of Directors, effective November 8, 2024. Mr. Bruehlman brings to GoodRx 39 years of finance experience in the healthcare services, industrial and petroleum industries. He currently serves as Chief Financial Officer of IQVIA, a global provider of advanced analytics, technology solutions, and contract research. Prior to IQVIA, he served as CFO of IMS Health and had a 23-year career at United Technologies Corporation, wh
New GoodRx research shows menopause medications have increased in price by over 50% over the last decade Today, GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., announced the availability of new affordability programs for menopause hormone therapies by Pfizer. Through the reach and scale of the GoodRx platform, these programs are broadening access and affordability of crucial medications for women. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241023067340/en/(Photo: Business Wire) New research from GoodRx shows menopause medications have increased in list price by 58% since 2014. And according to a
Approved users will now be able to select an Affirm payment plan for select medications directly on the GoodRx platform GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced consumers will soon be able to use Affirm to pay over time for select medications at participating retail pharmacies. This adds a convenient way for consumers to pay for their medications directly on the GoodRx platform. GoodRx is launching this program with its partner pharmacies, including Hy-Vee, a grocery retailer with a network of more than 275 retail pharmacies. Together, the companies are ensuring a seamless ecommerce experience for consumers. As an example, when a person
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced it will release its third quarter 2024 financial results before U.S. markets open on Thursday, November 7, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations website at https://inve
neffy is available in pharmacies this week and the lowest discounted cash price at retail pharmacies can be found exclusively at GoodRx neffy is the first and only needle-free treatment for Type I allergic reactions, including anaphylaxis for adults and children who weigh ≥30 kg (66 lbs.) GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced it is working with ARS Pharmaceuticals, Inc. ("ARS Pharmaceuticals") to offer the lowest discounted cash price for neffy® in retail pharmacy locations. Available for purchase in-store this week, consumers who have been prescribed neffy can now access a pack of two single-use neffy devices for $199 at more than 70
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced that executives from the Company will participate in a fireside chat at each of the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on Thursday, September 5, 2024 at 7:45 a.m. Eastern Time (4:45 a.m. Pacific Time) Wells Fargo 2024 Healthcare Conference in Boston, MA on Friday, September 6, 2024 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) A live webcast of each of the foregoing events will be available on the Company's Investor Relations website, https://investors.goodrx.com/. Following
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $200.6 million Net income of $6.7 million; Net income margin of 3.3% Adjusted Net Income1 of $32.4 million; Adjusted Net Income Margin1 of 16.1% Adjusted EBITDA1 of $65.4 million; Adjusted EBITDA Margin1 of 32.6% Net cash provided by operating activities of $9.7 million Exited the quarter with over 7 million consumers of prescription-related offerings2 "We're proud of the progress we're making against
First biosimilar with an exclusive low cash price on the GoodRx platform RIDGEFIELD, Conn. and SANTA MONICA, Calif., July 18, 2024 /PRNewswire/ -- Boehringer Ingelheim and GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., announced today a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer's biosimilar to Humira® (adalimumab), at a low cash price available exclusively on GoodRx. This program is a significant step in addressing access and affordability in one of the largest therapeutic categories with a high cost burden for patients.
Former Chief Financial Officer of The Honest Company brings over 25 years of experience across retail and consumer brands GoodRx (NASDAQ:GDRX), a leading resource for healthcare savings and information, today announced the election of Kelly J. Kennedy to its Board of Directors. Kennedy will serve as a member of the Board's audit committee and fill the seat left vacant by Jacqueline Kosecoff earlier this year. With over 25 years of experience serving in senior financial roles for leading retail and consumer brands, Kennedy brings extensive experience overseeing risk assessment management and financial reporting at large public companies. Currently, Kennedy serves as Chief Financial Offic
Amino Health, the leading digital healthcare navigation company, today announced the appointment of John Asalone to the role of Chief Executive Officer. He succeeds David Vivero, the company's visionary founder and CEO, who steps into a new role as Chairman. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231213064342/en/John Asalone, Amino Health CEO (Photo: Business Wire) Asalone, who joined Amino this past August as COO, is a seasoned executive with 20 years of experience scaling software and marketplace companies. Previously the SVP of Growth Verticals at GoodRx (NASDAQ:GDRX), Asalone specializes in bringing consumer-grade ex
Jim Emling, the CEO of Datassential and former long-time president of Milwaukee-based Zywave, has been appointed Executive Chair of the Board of Directors at VBA, the company announced today. "We are delighted to welcome Jim officially to VBA as the Executive Chair," said Michael Clayton, the company's President and CEO. "Jim and I have worked closely together over the last 3 months and his decades of experience scaling high growth software companies combined with his strong ties to the Milwaukee technology sector will be tremendous assets to VBA as we enter our next phase of growth." Emling has deep roots in the Milwaukee technology community. He was the founding CTO of Zywave and serv
Gemmell to co-lead Pharma Manufacturer Solutions business, oversee GoodRx Health and Provider Mode GoodRx (NASDAQ:GDRX), a leading resource for healthcare savings and information, today announced the appointment of Dorothy Gemmell as Chief Commercial Officer, effective July 3, 2023. Gemmell will work closely with Aaron Crittenden, newly appointed Chief Revenue Officer, and together they will lead the company's Pharma Manufacturer Solutions business, which provides solutions for pharmaceutical and medical device companies. Gemmell brings with her a strong track record leading high-growth teams and building trusted, market-leading healthcare companies that provide solutions to pharmaceuti
DocGo (NASDAQ:DCGO), a leading provider of last-mile mobile health services, today announced that it has appointed veteran human resources executive Vina Leite, MS, to its Board of Directors. Ms. Leite brings to the DocGo Board more than two decades of leadership, with experience transforming technology-driven high growth and Fortune 500 organizations by closely aligning human resources with corporate goals to achieve optimal outcomes. The company also announced key leadership promotions that will be effective December 31, 2022. "We are very pleased to have someone with Vina's experience and track record join our Board at this time," stated Stan Vashovsky, Chief Executive Officer and Chair
The company bolsters its leadership team with experienced mission-driven executives GoodRx (NASDAQ:GDRX), a leading consumer-focused digital healthcare platform, today announced it has made key leadership appointments to support the company's scaling business and accelerate innovation to bring more affordable and convenient healthcare to consumers across the country. Raj Beri will join GoodRx as the company's first ever Chief Operating Officer (COO) from Uber, where he served as Vice President of Grocery and New Verticals, overseeing the company's non-restaurant and last mile delivery businesses across global markets. With more than 20 years in the business operations space, Raj will lead
Acquires Savioke R&D, Relay® Product Line Names Michael O'Donnell Chairman & CEO Relay Robotics, Inc. — a new corporation formed by the acquisition of leading robotics developer Savioke — announced the completion of a $10,000,000 Series A Financing and the appointment of veteran technology executive, Michael O'Donnell, as Chairman and Chief Executive Officer. Savioke Co-Founder, Steve Cousins, will become Chief Technology Officer of Relay Robotics and lead the company's product strategy and innovation efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220501005046/en/Michael O'Donnell, Chairman and Chief Executive Officer,
8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
144 - GoodRx Holdings, Inc. (0001809519) (Subject)
10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)
8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
DEFA14A - GoodRx Holdings, Inc. (0001809519) (Filer)
8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)
Boehringer Ingelheim and GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., announced today a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer's biosimilar to Humira® (adalimumab), at a low cash price available exclusively on GoodRx. This program is a significant step in addressing access and affordability in one of the largest therapeutic categories with a high cost burden for patients. Adalimumab-adbm is an FDA-approved interchangeable* biosimilar to Humira®. The citrate-free, injectable medication is used to treat or reduce the signs and symptoms of certain autoimmune conditions, such as rheumatoid arthritis, Crohn's diseas
U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Monday. Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply during Monday's session amid a rise Bitcoin. Bitcoin prices rose past the key $63,000 level on Monday. MicroStrategy shares jumped 11.5% to $1,556.89 during the session. Here are some other big stocks recording gains in today’s session. Trump Media & Technology Group Corp. (NASDAQ:DJT) shares jumped 32.8% to $41.03 following the attempted assassination of Donald Trump. The company's CEO Devin Nunes issued the following statement in response to the attempted assassination of President Donald J. Trump, “I offer my deepest sympath
Reveals Consumers Paid $21B Out-of-Pocket in 2024, Averaging $16.26 Per Prescription
Throughout the last three months, 7 analysts have evaluated GoodRx Holdings (NASDAQ:GDRX), offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 5 1 0 0 Last 30D 0 0 1 0 0 1M Ago 1 3 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for GoodRx Holdings, presenting an average target of $10.64, a high estimate of $
Morgan Stanley analyst Craig Hettenbach maintains GoodRx Holdings (NASDAQ:GDRX) with a Equal-Weight and raises the price target from $7 to $9.5.
RBC Capital Markets issued an upgrade for GoodRx Holdings Inc (NASDAQ:GDRX) shares. The analyst stated the Integrated Savings Program (ISP) and direct contracting (DC) initiatives, along with the expansion of its manufacturing solutions business, offered significant new growth opportunities and strengthened the stability of its core Rx transaction business. Related: Change Healthcare Cyberattack: GoodRx Expects Low Single Digit Million-Dollar Impact In 2024. “We think this ‘hybrid’ approach presents both some incremental revenue opportunity while also better insulating GDRX from PBM-retailer disruptions like what happened with Kroger in mid-2022,” RBC wrote. GoodRx announced a ne
RBC Capital analyst Mark Mahaney upgrades GoodRx Holdings (NASDAQ:GDRX) from Sector Perform to Outperform and raises the price target from $8 to $10.
Barclays analyst Stephanie Davis maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and raises the price target from $9 to $10.
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced it will release its third quarter 2024 financial results before U.S. markets open on Thursday, November 7, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations website at https://inve
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $200.6 million Net income of $6.7 million; Net income margin of 3.3% Adjusted Net Income1 of $32.4 million; Adjusted Net Income Margin1 of 16.1% Adjusted EBITDA1 of $65.4 million; Adjusted EBITDA Margin1 of 32.6% Net cash provided by operating activities of $9.7 million Exited the quarter with over 7 million consumers of prescription-related offerings2 "We're proud of the progress we're making against
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced it will release its second quarter 2024 financial results before U.S. markets open on Thursday, August 8, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations website at https://inve
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading destination for prescription savings in the U.S., has released its financial results for the first quarter of 2024. First Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $197.9 million Net loss of $1.0 million; Net loss margin of 0.5% Adjusted Net Income1 of $32.6 million; Adjusted Net Income Margin1 of 16.5% Adjusted EBITDA1 of $62.8 million; Adjusted EBITDA Margin1 of 31.7% Net cash provided by operating activities of $42.6 million Exited the quarter with approximately 8 million consumers of prescription-related offerings2 "I'm encouraged by the strides we've m
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., today announced it will hold its first Investor Day on May 15, 2024, in New York City. The event will begin at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). The event will feature presentations by GoodRx's Interim CEO, Scott Wagner; CFO, Karsten Voermann; as well as other leaders from across the Company and will include an overview of the company's business drivers and its strategy for long-term growth, followed by a Q&A session. A link to access the live webcast, as well as any related materials, will be available on GoodRx's investor relations website at ht
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., today announced it will release its first quarter 2024 financial results before U.S. markets open on Thursday, May 9, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations website at https://i
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., has released its financial results for the fourth quarter and full year 2023, which are consistent with its preliminary results announced on January 10, 2024. Fourth Quarter 2023 Highlights Revenue1 and Adjusted Revenue1,2 of $196.6 million Net loss of $25.9 million; Net loss margin of 13.2% Adjusted Net Income2 of $31.1 million; Adjusted Net Income Margin2 of 15.8% Adjusted EBITDA2 of $57.3 million; Adjusted EBITDA Margin2 of 29.1% Net cash provided by operating activities of $15.9 million Exited the quarter with over 7 million consumers of pres
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S, today announced it will release its fourth quarter and full year 2023 financial results before U.S. markets open on Thursday, February 29, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), a leading resource for healthcare savings and information, today announced it will release its third quarter 2023 financial results before U.S. markets open on Thursday, November 9, 2023. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations website at https:/
Second quarter financial results exceed previously announced guidance GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), a leading resource for healthcare savings and information, has released its financial results for the second quarter 2023. Second Quarter 2023 Highlights Total revenue of $189.7 million, exceeding previously announced guidance Net income of $58.8 million1; Net income margin of 31.0% Adjusted Net Income2 of $28.4 million; Adjusted Net Income Margin2 of 15.0% Adjusted EBITDA2 of $53.5 million; Adjusted EBITDA Margin2 of 28.2%, exceeding previously announced guidance Net cash provided by operating activities of $29.9 million Over 500,000 p
Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00
RBC Capital Mkts upgraded GoodRx from Sector Perform to Outperform and set a new price target of $10.00 from $8.00 previously
Raymond James upgraded GoodRx from Mkt Perform to Outperform and set a new price target of $10.00
KeyBanc Capital Markets upgraded GoodRx from Sector Weight to Overweight and set a new price target of $9.00
Wells Fargo upgraded GoodRx from Equal Weight to Overweight and set a new price target of $10.00 from $7.50 previously
JP Morgan upgraded GoodRx from Neutral to Overweight and set a new price target of $10.00 from $7.00 previously
Leerink Partners initiated coverage of GoodRx with a rating of Outperform and set a new price target of $8.00
BofA Securities downgraded GoodRx from Buy to Underperform and set a new price target of $4.50 from $8.00 previously
DA Davidson upgraded GoodRx from Neutral to Buy and set a new price target of $9.50
TD Cowen upgraded GoodRx from Market Perform to Outperform and set a new price target of $12.00 from $6.50 previously